9Apr2015 Which Big Public Investors Are ‘Crossing Over’ Into the Private Arena? /Luke Timmerman/1/All, Finance, Venture Capital09 Apr 2015 Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.